BRPI0912539A2 - composto, composição farmacêutica , método para tratar uma doença, e, uso do composto. - Google Patents
composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.Info
- Publication number
- BRPI0912539A2 BRPI0912539A2 BRPI0912539A BRPI0912539A BRPI0912539A2 BR PI0912539 A2 BRPI0912539 A2 BR PI0912539A2 BR PI0912539 A BRPI0912539 A BR PI0912539A BR PI0912539 A BRPI0912539 A BR PI0912539A BR PI0912539 A2 BRPI0912539 A2 BR PI0912539A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- disease
- treating
- pharmaceutical composition
- pharmaceutical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12648008P | 2008-05-05 | 2008-05-05 | |
| US12743408P | 2008-05-13 | 2008-05-13 | |
| PCT/US2009/042711 WO2009137404A1 (en) | 2008-05-05 | 2009-05-04 | Urea compounds as gamma secretase modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0912539A2 true BRPI0912539A2 (pt) | 2015-10-13 |
Family
ID=41010229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0912539A BRPI0912539A2 (pt) | 2008-05-05 | 2009-05-04 | composto, composição farmacêutica , método para tratar uma doença, e, uso do composto. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20110118234A1 (pt) |
| EP (1) | EP2300427A1 (pt) |
| JP (1) | JP2011520809A (pt) |
| CN (1) | CN102083794A (pt) |
| AU (1) | AU2009244504A1 (pt) |
| BR (1) | BRPI0912539A2 (pt) |
| CA (1) | CA2722606A1 (pt) |
| IL (1) | IL209025A0 (pt) |
| MX (1) | MX2010011920A (pt) |
| WO (1) | WO2009137404A1 (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007336781C1 (en) * | 2006-12-21 | 2014-10-09 | Sloan-Kettering Institute For Cancer Research | Pyridazinones and furan-containing compounds |
| EP2408753A4 (en) * | 2009-03-20 | 2012-11-07 | Univ Brandeis | COMPOUNDS AND METHOD FOR THE TREATMENT OF MICROBIAL STOMACH DARM INFECTIONS IN MAMMALS |
| MX2012008530A (es) * | 2010-01-25 | 2013-02-21 | Kareus Therapeutics Sa | NUEVAS COMPOSICIONES PARA REDUCIR LA PRODUCCION DE Aß 42 Y SU USO PARA TRATAR LA ENFERMEDAD DE ALZHEIMER (AD). |
| WO2012131539A1 (en) | 2011-03-31 | 2012-10-04 | Pfizer Inc. | Novel bicyclic pyridinones |
| US9447134B2 (en) | 2012-08-17 | 2016-09-20 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| AR097279A1 (es) * | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx |
| EP3076789A4 (en) * | 2013-12-04 | 2017-11-22 | The Scripps Research Institute | Novel compounds as jnk kinase inhibitors |
| TN2017000342A1 (en) | 2015-02-03 | 2019-01-16 | Pfizer | Novel cyclopropabenzofuranyl pyridopyrazinediones |
| US10100015B2 (en) * | 2015-03-24 | 2018-10-16 | Shanghai Yingli Pharmaceutical Co., Ltd. | Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof |
| EP3621951A4 (en) * | 2017-05-12 | 2021-01-27 | Research Triangle Institute | DIARYL URINE AS CB1 ALLOSTERIC MODULATORS |
| CA3093546A1 (en) * | 2018-03-28 | 2019-10-03 | Hanlim Pharmaceutical Co., Ltd. | 2-cyanopyrimidin-4-yl carbamate or urea derivative or salt thereof, and pharmaceutical composition including same |
| EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CR20230576A (es) * | 2021-06-14 | 2024-04-05 | Scorpion Therapeutics Inc | Derivados de la urea que pueden ser utilizados para tratar el cáncer |
| EP4598919A1 (en) * | 2022-10-07 | 2025-08-13 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| WO2025190317A1 (en) * | 2024-03-13 | 2025-09-18 | National Institute Of Biological Sciences, Beijing | Urea compounds as nlrp3 agonists |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376775A (en) * | 1980-05-27 | 1983-03-15 | Sterling Drug Inc. | N-[4-(4-Pyridinyl)phenyl]ureas and their cardiotonic use |
| JP2577222B2 (ja) * | 1987-04-10 | 1997-01-29 | 興和株式会社 | 新規な置換アニリド誘導体 |
| US5077409A (en) * | 1990-05-04 | 1991-12-31 | American Cyanamid Company | Method of preparing bis-aryl amide and urea antagonists of platelet activating factor |
| JP4073489B2 (ja) * | 1996-05-24 | 2008-04-09 | ニューロサーチ・アクティーゼルスカブ | 酸性基を有するフエニル誘導体、その製造方法及びそれをクロライドチャンネル遮断剤として使用する方法 |
| US5773469A (en) * | 1996-06-18 | 1998-06-30 | Ortho Pharmaceutical Corporation | Diaryl antimicrobial agents |
| JP2001512727A (ja) * | 1997-08-09 | 2001-08-28 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ５ｈｔ−１受容体のリガンドとしてのニ環式化合物 |
| US7041675B2 (en) * | 2000-02-01 | 2006-05-09 | Abbott Gmbh & Co. Kg | Heterocyclic compounds and their use as PARP inhibitors |
| PT1300396E (pt) * | 2000-06-12 | 2009-04-20 | Eisai R&D Man Co Ltd | Compostos de 1,2-di-hidropiridina, processos para a sua preparação e sua utilização |
| WO2002000647A1 (en) * | 2000-06-23 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
| US6884806B2 (en) * | 2001-10-17 | 2005-04-26 | Bristol-Myers Squibb Company | Bicyclic lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| US20030216396A1 (en) * | 2002-02-11 | 2003-11-20 | Bayer Corporation | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
| EP2324825A1 (en) * | 2002-02-11 | 2011-05-25 | Bayer Healthcare LLC | Aryl ureas with angiogenesis inhibiting activity |
| DE10238002A1 (de) * | 2002-08-20 | 2004-03-04 | Merck Patent Gmbh | Benzimidazolderivate |
| AU2003282920A1 (en) * | 2002-10-04 | 2004-05-04 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) |
| AU2003284001A1 (en) * | 2002-10-07 | 2004-05-04 | Bristol-Myers Squibb Company | Triazolone and triazolethione derivatives |
| US7202257B2 (en) * | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| US20050267182A1 (en) * | 2003-11-13 | 2005-12-01 | Ambit Biosciences Corporation | Urea derivatives as FLT-3 modulators |
| TW200529849A (en) * | 2003-11-28 | 2005-09-16 | Novartis Ag | Diaryl urea derivatives in the treatment of protein kinase dependent diseases |
| GB0406279D0 (en) * | 2004-03-19 | 2004-04-21 | Arrow Therapeutics Ltd | Therapeutic compounds |
| US20090239841A1 (en) * | 2004-10-27 | 2009-09-24 | Hutchison Alan J | Diaryl Ureas as CB1 Antagonists |
| GT200500321A (es) * | 2004-11-09 | 2006-09-04 | Compuestos y composiciones como inhibidores de proteina kinase. | |
| CA2587207A1 (en) * | 2004-11-23 | 2006-06-01 | Merck & Co., Inc. | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
| GB0428514D0 (en) * | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| US7622583B2 (en) * | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| TWI378925B (en) * | 2005-01-14 | 2012-12-11 | Gilead Connenticut Inc | Certain substituted ureas as modulators of kinase activity |
| US7842809B2 (en) * | 2005-01-24 | 2010-11-30 | Bayer Schering Pharma Ag | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same |
| GB0501999D0 (en) * | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| WO2006099075A2 (en) * | 2005-03-10 | 2006-09-21 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| WO2007024294A2 (en) * | 2005-05-03 | 2007-03-01 | Cgi Pharmaceuticals, Inc. | Certain substituted ureas, as modulators of kinase activity |
| FR2887548B1 (fr) * | 2005-06-27 | 2007-09-21 | Sanofi Aventis Sa | Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique |
| MX2007015679A (es) * | 2005-06-30 | 2008-02-21 | Amgen Inc | Inhibidores de quinasa bis-aril y su uso en el tratamiento de inflamacion, angiogenesis y cancer. |
| FR2888237B1 (fr) * | 2005-07-08 | 2007-08-31 | Sanofi Aventis Sa | Derives de n-[(4,5-diphenylpyrimidin-2-yl)methyl] amine, leur preparation et leur application en therapeutique |
| US8211919B2 (en) * | 2005-09-02 | 2012-07-03 | Astellas Pharma Inc. | Amide derivatives as rock inhibitors |
| FR2894578B1 (fr) * | 2005-12-12 | 2008-02-01 | Sanofi Aventis Sa | Derives heterocycliques, leur preparation et leur application en therapeutique. |
| FR2894579B1 (fr) * | 2005-12-12 | 2008-01-18 | Sanofi Aventis Sa | Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique. |
| EP1959947A2 (en) * | 2005-12-15 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
| US7825120B2 (en) * | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| TW200815438A (en) * | 2006-06-13 | 2008-04-01 | Bayer Schering Pharma Ag | Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| WO2008042867A2 (en) * | 2006-09-29 | 2008-04-10 | Emiliem Inc. | Modulators of multiple kinases |
| CA2707492A1 (en) * | 2007-12-13 | 2009-06-18 | Amgen Inc. | Gamma secretase modulators |
-
2009
- 2009-05-04 CN CN2009801270096A patent/CN102083794A/zh active Pending
- 2009-05-04 EP EP09743390A patent/EP2300427A1/en not_active Withdrawn
- 2009-05-04 WO PCT/US2009/042711 patent/WO2009137404A1/en not_active Ceased
- 2009-05-04 BR BRPI0912539A patent/BRPI0912539A2/pt not_active IP Right Cessation
- 2009-05-04 US US12/990,999 patent/US20110118234A1/en not_active Abandoned
- 2009-05-04 AU AU2009244504A patent/AU2009244504A1/en not_active Abandoned
- 2009-05-04 CA CA2722606A patent/CA2722606A1/en not_active Abandoned
- 2009-05-04 JP JP2011508576A patent/JP2011520809A/ja not_active Withdrawn
- 2009-05-04 MX MX2010011920A patent/MX2010011920A/es not_active Application Discontinuation
-
2010
- 2010-10-31 IL IL209025A patent/IL209025A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2010011920A (es) | 2010-11-26 |
| IL209025A0 (en) | 2011-01-31 |
| WO2009137404A1 (en) | 2009-11-12 |
| CA2722606A1 (en) | 2009-11-12 |
| AU2009244504A1 (en) | 2009-11-12 |
| EP2300427A1 (en) | 2011-03-30 |
| JP2011520809A (ja) | 2011-07-21 |
| CN102083794A (zh) | 2011-06-01 |
| US20110118234A1 (en) | 2011-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0917705A2 (pt) | composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto | |
| BRPI0819755A2 (pt) | composto, composição farmacêutica, processos para a preparação de um composto e de uma composição farmacêutica, uso de um composto, e, método para tratar ou reduzir o risco de uma doença ou uma condição inflamatória | |
| BRPI1013984A2 (pt) | composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto. | |
| BRPI1015983A2 (pt) | composto, uso do composto, método para tratar um paciente, e, composição farmacêutica. | |
| BRPI0922475A2 (pt) | composto, composição farmacêutica , método para tratar câncer, e, uso de um composto. | |
| BRPI0911685A2 (pt) | composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit | |
| BRPI0819218A2 (pt) | Métodos, estojos e composições para administração de compostos farmacêuticos | |
| BRPI0813237A2 (pt) | Composto, método para preparar o composto, composição, medicamento, e, uso do composto. | |
| BRPI0915382A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio. | |
| BR112012016398A2 (pt) | Composto imidazopiridinil-aminopiridino substituído, composição farmacêutica que compreende o referido composto e uso do mesmo para o tratamento de uma doença celular proliferativa | |
| BRPI0814503A2 (pt) | composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica | |
| BRPI0917458A2 (pt) | composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto | |
| BRPI0907976A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
| BRPI0819799A2 (pt) | Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença | |
| BRPI0818244A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença | |
| BRPI0820474A2 (pt) | método de tratamento de uma doença, uso de composto, e, composto | |
| BRPI0814688A2 (pt) | composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar doenças, e, composição farmacêutica | |
| BRPI0815057A2 (pt) | Composto, composição farmacêutica, e, método para tratar infecção. | |
| BRPI0916689A2 (pt) | composição farmacêutica estabilizada, preparação sólida, e, métodos para estabilizar uma composição farmacêutica, e para estabilizar uma preparação sólida. | |
| BRPI0815591A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio. | |
| BR122020011920A2 (pt) | composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto | |
| BR112012003280A2 (pt) | composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto. | |
| BRPI0914918A2 (pt) | forma de dosagem farmacêutica, e, método para preparar uma forma de dosagem sólida. | |
| BR112012004333A2 (pt) | composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio. | |
| BRPI1013396A2 (pt) | composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |